Stay updated with breaking news from ஏவுதல் டைனமிக்ஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Aduhelm Launch Trends Show Some Early Signs Of Progress As The Biogen Team Aims To Moderate Near-Term Expectations, According To Spherix Global Insights prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Nephrologists have long considered chronic kidney disease (CKD) progression and diabetic kidney disease (DKD) as areas in dire need of new and. ....
/PRNewswire/ The Lupus Foundation of America estimates that 1.5 million Americans, and at least five million people worldwide, have a form of lupus.[1] As. ....
Share this article Share this article EXTON, Pa., Feb. 17, 2021 /PRNewswire/ Approved just two weeks apart in June of last year for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA), in-class competitors, Novartis Cosentyx and Eli Lilly s Taltz, have since experienced rapid uptake. According to feedback from 97 US rheumatologists in the latest report included in Spherix s RealTime Dynamix ™ service, the official entrance of the IL-17 inhibitors is causing a shift in the market where UCB s Cimzia previously held the position as the only biologic with commercial availability. The report, which highlights the differences in referral, diagnostic, and management patterns of ankylosing spondylitis (AS) and nr-axSpA patients, found that the incidence of biologic/JAK treatment (including off-label use) remains higher in AS than it does in nr-axSpA. However, biologic treatment in moderate and severe forms of nr-axSpA has seen growth over the la ....
Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets The Launch Dynamix™ service includes current tracking of Cosentyx (Novartis) and Taltz (Eli Lilly) in non-radiographic axial spondyloarthritis, Kesimpta (Novartis) in multiple sclerosis, Stelara (Janssen) in ulcerative colitis, Tremfya (Janssen) in psoriatic arthritis, and Benlysta (GSK) and Lupkynis (Aurinia) in lupus nephritis News provided by Share this article Share this article EXTON, Pa., Jan. 29, 2021 /PRNewswire/ Spherix Global Insights, a leading market intelligence firm specializing in select dermatology, gastroenterology, nephrology, neurology, and rheumatology markets, announces the inaugural publications of their newest service offering, ....